



PRESS RELEASE

Lipidor submits new patent application and expands collaboration with Cannasure using Lipidor's AKVANO® technology for medicinal cannabis products

Stockholm, Sweden, 29 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announced that the collaboration agreement with Cannasure Therapeutics has expanded to include a new patent family covering new innovative AKVANO® topical compositions. Lipidor submitted the new patent application to the European Patent Office on 25 October 2021.

Earlier this year, Lipidor signed an exclusive licensing agreement with Cannasure Therapeutics for the use of Lipidor's patented drug delivery technology AKVANO® in topical medical cannabis products, and the programs are progressing according to expectations. Cannasure Therapeutics plans to apply for approvals to conduct Phase I/IIa clinical trials with medicinal cannabis products for psoriasis and pain treatments during 2022. The results from these clinical studies would be expected in H1 2023.

Swedish R&D company Lipidor AB and Cannasure Therapeutics Ltd, an Israeli commercial medical cannabis company whose operations include the entire medical cannabis value chain, report that the programs for the medicinal cannabis products using AKVANO® technology are progressing to expectations. Additional preclinical data confirm the potential benefits of using AKVANO® for cannabinoids. The next milestone is to submit the clinical study protocols to the Israeli Ministry of Health for their review and approval. Cannasure Therapeutics expects to apply for approvals to conduct a Phase I/IIa clinical trial with a medicinal cannabis product for the treatment of psoriasis in Q1 2022 as well as an application for a Phase I/IIa clinical study for pain treatment in H2 2022. Pending the approvals and completion of the trials, the results from the clinical studies are expected in H1 2023.

In line with Lipidor's strategy, the company is continuously looking into and undertaking work to further strengthen and extend patent protections for the AKVANO® technology. Based on new IP (intellectual property), the scope of the collaboration agreement has expanded to include a new patent family covering innovative new AKVANO® topical formulations. Lipidor submitted a new priority patent application to the European Patent Office (EPO) on October 25, 2021.

There is a significant unmet need for topical pain and psoriasis therapies, and in both indications the possibility to use an AKVANO® formulation as a non-touch spray is expected to make the treatment more convenient for the patient. Cannabinoids based products are novel, involve new mechanism of action, are safe and tolerable and have the potential to improve quality of life for patients which do not benefit from current products on the market.

"We are delighted that Cannasure Therapeutics' programs, using Lipidor's AKVANO® technology in the development of topical medicinal cannabis products, are progressing well. Furthermore, we are pleased to expand the scope of our collaboration agreement with Cannasure since the exclusive licensing agreement represents a significant commercial potential for Lipidor and an external validation of our unique formulation platform, showing that cannabinoids can also be well incorporated into AKVANO®. We have great faith in Cannasure moving forward as well as high expectations on the partnership with the aim to commercialize innovative new products as soon as possible," says Ola Holmlund, CEO of Lipidor.



PRESS RELEASE

In light of the outbreak of the coronavirus and Covid-19, Lipidor is closely monitoring developments and taking measures to minimize or eliminate the impact on the company's operations. To date, the Covid-19 pandemic has had a limited effect on Lipidor's operations, but the company may need to revise its schedules if the pandemic is prolonged.

The initiation of the clinical studies followed by the anticipated results timelines is subject to approval by the Israeli Cannabis Unit and the Israeli Ministry of Health.

The information was submitted for publication, through the office of Lipidor's CEO, on 29 October 2021, at 2.45 pm CEST.

For more information, please contact:

Ola Holmlund, CEO

Telephone: +46 (0)72 50 70 369

Email: ola.holmlund@lipidor.se

Certified Adviser

Erik Penser Bank AB

Telephone: +46 (0)8 463 80 00

E-mail: certifiedadviser@penser.se

About AKVANO®

AKVANO® is an innovative water-free and sprayable technology for the formulation of drugs and is particularly suitable for local application to, for example, the skin. AKVANO® is made up of carefully selected lipids which, together with a volatile solvent, constitute carriers of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of active components in the formulation. When applied to the skin, the solvent evaporates, and a thin lipid layer is formed on the skin surface for effective release of the active substance.

About Lipidor

Lipidor AB (publ) (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis, by reformulation of proven pharmaceutical substances.

About Cannassure

Cannassure Therapeutics Ltd. (TASE:CSURE) is developing innovative pharmaceutical dermatology unique formulations based on cannabinoids combined with established drug delivery patent technologies for enhanced therapeutic value targeting multi-billion dollar market. The company was founded by Solbar, a leading botanical extraction specialist with 60 years of experience and track record as a trusted supplier to leading international pharmaceutical companies including Novartis, Bayer and others. www.cannassure.life/